Cardiovascular event rates in atorvastatin patients versus patients switching from atorvastatin to simvastatin

References

• IMS Health. Top therapeutic classes by US dispensed prescriptions. Top-line market data: 2008 US sales and prescription information. Available at: http://www.imshealth.com/deployedfiles/imshealth/Global/Content/StaticFile/Top_Line_Data/2008_Top_Therapy_Classes_By_U.S._RX.pdf [Last accessed 24 January 2012]
   Google Scholar
• Frisch W. Savings expected from shift to generic cholesterol drugs. The University Record Online. January 4, 2007. Available at: http://www.ur.umich.edu/0607/Dec11_06/01.shtml [Last accessed 24 January 2012]
   Google Scholar
• Sy FZ, Choe HM, Kennedy DM, et al. Moving from A to Z: successful implementation of a statin switch program by a large physician group. Am J Manag Care 2009;15:233-40
   PubMed Web of Science ®Google Scholar
• Cheetham TC, Chan J, Benson V, et al. Successful conversion of patients with hypercholesterolemia from a brand name to a generic cholesterol-lowering drug. Am J Manag Care 2005;11:546-52
   PubMed Web of Science ®Google Scholar
• Billups SJ, Plushner SL, Olson KL, et al. Clinical and economic outcomes of conversion of simvastatin to lovastatin in a group-model health maintenance organization. J Manag Care Pharm 2005;11:681-6
   PubMedGoogle Scholar
• Patel RJ, Gray DR, Pierce R, et al. Impact of therapeutic interchange from pravastatin to lovastatin in a Veterans Affairs Medical Center. Am J Manag Care 1999;5:465-74
   PubMed Web of Science ®Google Scholar
• Ridley DB, Axelsen KJ. Impact of Medicaid preferred drug lists on therapeutic adherence. Pharmacoeconomics 2006;24(Suppl 3):65-78
   PubMedGoogle Scholar
• Usher-Smith JA, Ramsbottom T, Pearmain H, et al. Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting. Int J Clin Pract 2007;61:15-23
   PubMed Web of Science ®Google Scholar
• Chapman RH, Benner JS, Girase P, et al. Generic and therapeutic statin switches and disruptions in therapy. Curr Med Res Opin 2009;25:1247-60
   PubMed Web of Science ®Google Scholar
• Bestehorn K, Greiner W. Effects of the introduction of fixed prices for statins on lipid levels in Germany. J Public Health 2008;16:215-19
   Google Scholar
• Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002;288:462-7
   PubMed Web of Science ®Google Scholar
• Phillips B, Roberts C, Rudolph AE, et al. Switching statins: the impact on patient outcomes. Br J Cardiol 2007;14:280-5
   Google Scholar
• Aronow HD, Hess G, Hill J, et al. Switching from atorvastatin to simvastatin in patients at high cardiovascular risk: effect on low-density lipoprotein cholesterol. Am J Therapeutics 2010;17:167-75
   PubMed Web of Science ®Google Scholar
• Rublee DA, Burke JP. LDL-C goal attainment in patients who remain on atorvastatin or switch to equivalent or non-equivalent doses of simvastatin: a retrospective matched cohort study in clinical practice. Postgrad Med 2010;122:16-24
   PubMed Web of Science ®Google Scholar
• Pedersen TR, Faergeman O, Kastelein JJ, et al. High dose atorvastatin vs. usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005;294:2437-45, published correction appears in JAMA 2005;294:3092
   PubMed Web of Science ®Google Scholar
• Nawrocki JW, Weiss SR, Davidson MH, et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 1995;15:678-82
   PubMed Web of Science ®Google Scholar
• Athyros VG, Papageorgiou AA, Mercouris BR, et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus ‘usual’ care in secondary coronary heart disease prevention: the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin 2002;18:220-8
   PubMed Web of Science ®Google Scholar
• Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504, published correction appears in N Engl J Med 2006;354:778
   PubMed Web of Science ®Google Scholar
• Koren MJ. Statin use in a ‘real-world’ clinical setting: aggressive lipid lowering compared with usual care in the Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE) trial. Am J Med 2005;118:16-21S
   PubMed Web of Science ®Google Scholar
• LaRosa JC, Grundy S, Waters DD. Intensive lipid lowering with atorvastatin provides early and sustained benefit in patients with stable coronary disease: a secondary analysis of the Treating to New Targets (TNT) study [abstract 3728]. Circulation 2006;114(Suppl 2):796
   Google Scholar
• LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35
   PubMed Web of Science ®Google Scholar
• Pasceri V, Patti G, Nusca A, et al. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2004;110:674-8
   PubMed Web of Science ®Google Scholar
• Pitt B, Waters D, Brown WV, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med 1999;341:70-6
   PubMed Web of Science ®Google Scholar
• Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001;285:1711-18
   PubMed Web of Science ®Google Scholar
• Scandinavian Simvastatin Survival Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9
   PubMed Web of Science ®Google Scholar
• Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78. Epub 2005 Sep 27
   PubMed Web of Science ®Google Scholar
• Rogers SL, Magliano DJ, Levison DB, et al. A dose-specific meta-analysis of lipid changes in randomized controlled trials of atorvastatin and simvastatin. Clin Ther 2007;29:242-52
   PubMed Web of Science ®Google Scholar
• Hess G, Sanders KN, Hill J, et al. Therapeutic dose assessment of patient switching from atorvastatin to simvastatin. Am J Manag Care 2007;13:80-85S
   PubMed Web of Science ®Google Scholar
• Schneeweiss S, Maclure M, Dormuth CR, et al. A therapeutic substitution policy for proton pump inhibitors: clinical and economic consequences. Clin Pharmacol Ther 2006;79:379-88
   PubMed Web of Science ®Google Scholar
• Minhas R, Bogle RG, Patel KC, Moon JC. Pharmacopolitics, statin switching and therapeutic substitution: much ado about something. Int J Clin Pract 2008;62:354-5
   PubMed Web of Science ®Google Scholar
• Colivicchi F, Tubaro M, Santini M. Clinical implications of switching from intensive to moderate statin therapy after acute coronary syndromes. Int J Cardiol 2011;152:56-60
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83
   PubMedGoogle Scholar
• Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-19
   PubMed Web of Science ®Google Scholar
• McKenney JM, Jones PH, Adamczyk MA, et al. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr Med Res Opin 2003;19:689-98
   PubMed Web of Science ®Google Scholar
• Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 2003;92:152-60
   PubMed Web of Science ®Google Scholar
• Fox KM, Gandhi SK, Ohsfeldt RL, Davidson MH. Comparison of low-density lipoprotein cholesterol reduction after switching patients on other statins to rosuvastatin or simvastatin in a real-world clinical practice setting. Am J Manag Care 2007;13(Suppl 10):270-5S
   Google Scholar
• Raal FJ. A single-centre retrospective observational study to evaluate the change in total cholesterol and LDL cholesterol in hyperlipidaemic patients switched from atorvastatin to simvastatin. Cardiovasc J S Afr 2004;15:118-23
   PubMedGoogle Scholar
• Stargardt T. The impact of reference pricing on switching behavior and healthcare utilization: the case of statins in Germany. Eur J Health Econ 2010;11:267-77
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence. Statins for the prevention of cardiovascular events (TAO94). November 2008. Available at: http://www.nice.org.uk/nicemedia/live/11564/33151/33151.pdf [Last accessed 24 January 2012]
   Google Scholar
• Usher-Smith K, Ramsbottom T, Pearmain H, et al. Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on. Int J Clin Pract 2008;62:480-4
   PubMed Web of Science ®Google Scholar
• McCormack T, Minhas R. Switching statins: do it, but do it properly. Br J Cardiol 2007;14:251-2
   Google Scholar